Cypher versus Taxus: the stent war.
Cypher (sirolimus-eluting stent) and Taxus (paclitaxel-eluting stent) have been approved for use in percutaneous coronary intervention. Both of the stents have shown superiority over bare metal stents in reducing major adverse cardiac events, restenosis rates and target vessel revascularisation. Results of clinical trials with head-to-head comparison of Taxus and Cypher stents in patients with obstructive coronary artery diseases have recently been reported. This review compares the performance of Cypher and Taxus stents as noted in observational studies and clinical trials in various types of coronary artery lesions.
Shafiq
Nusrat
N
Postgraduate Institute of Medical Education and Research, Department of Pharmacology, Chandigarh, 160012, India.
Malhotra
Samir
S
Pandhi
Promila
P
Behl
Ajay
A
Sharma
Yash Paul
YP
D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications / Q000188:drug therapy / Q000628:therapy; D004343:Drug Implants; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015607:Stents; D016896:Treatment Outcome
D004343:Drug Implants; D017239:Paclitaxel; D020123:Sirolimus